Skin cancer research gets $1 mil.
This article was originally published in The Rose Sheet
Executive Summary
National Cancer Institute grants $1 mil. to a University of Connecticut research team to develop a topical treatment that prevents and repairs sun damage leading to skin cancer, UConn states in Nov. 8 release. Researchers say they will develop the treatment using alpha-melanocyte stimulating hormone (alpha-MSH), which increases skin pigmentation to reduce UV penetration and "repair precancerous damage that UV rays do to skin cell DNA." Melanoma, the deadliest form of skin cancer, only occurs in 8% of skin cancer cases, but "causes almost all skin cancer deaths, and its incidence is rising at the rate of 4% per year," according to the statement. "The impact of this grant is potentially tremendous," study leader Zalfa Abdel-Malek, PhD, said. The treatment would be especially beneficial to fair-skinned people and others who generally carry a high risk for skin cancer, Abdel-Malek added...
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.